Stock Updates

How has Regeneron Pharmaceuticals, Inc.:(NASDAQ:REGN) performed recently?

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a large market cap stock with a market cap of 39176.53. It is in the Biotechnology industry and sector Healthcare, with a current P/E of 60.59, a forward P/E of 24.92 and EPS of 6.3. At a stock price of 375.26 (-1.65%) it has a dividend yield of *TBA.

EPS growth for the last five years have been 44.90%, more recently this last year it has grown by 85.10%. The next year growth is going to be about 41.75% and more long-term 19.09% after five years. EPS growth quarter over quarter is 118.60%. Sales growth for the past five years have been 55.00% and sales growth quarter over quarter is 38.10%.

For performance, Regeneron Pharmaceuticals, Inc. the past week has seen a gain of 1.54%. For the last month performance for Regeneron Pharmaceuticals, Inc. is 4.10%. While the last quarter is -9.67% and half year, -17.59%. Finally for the year, performance is -30.88%.

The 52-week high for Regeneron Pharmaceuticals, Inc., is at -38.07%, and for the 52-week low it comes to a value of 14.03%. The 20-day simple moving average is 0.29% and -15.22% for the 200-day simple moving average.

Volatility for the week is at 2.70%, and for the month it is 2.97%. Regeneron Pharmaceuticals, Inc., has a target price of 468.14.

In terms of debt, long term debt/equity is 0.1, and for total debt/equity Regeneron Pharmaceuticals, Inc. has 0.1. The gross margin is 90.50%, while operating margin is 28.90%, the profit margin is 16.40%. The current ratio is 3.4 and the quick ratio is 3.1.

Insider ownership is at 0.50%, with instituitional ownership at 71.30%. Regeneron Pharmaceuticals, Inc. has a payout ratio of 0.00%. With the total shares outstanding coming to 102.68. The shares float is 77.33, with the float short at 5.04%, with short ratio coming to 4.33.

In terms of returns, the return on assets see Regeneron Pharmaceuticals, Inc., get 13.70%, with its returns on investment at 16.00%. Return on equity is 20.70%. So will the investors see the target price of 468.14, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Peter Clarke

Leave a Comment